XKRX
298380
Market cap2.72bUSD
Jul 29, Last price
77,900.00KRW
1D
-4.18%
1Q
19.48%
IPO
322.22%
Name
ABL Bio Inc
Chart & Performance
P/E
—
P/S
113.17
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
33.40b
-49.04%
Net income
-55.53b
L+1,998.09%
CFO
-69.40b
L+144.70%
Earnings
Aug 11, 2025
Profile
ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline drugs include ABL001, cancer immunotherapy, ADC, and ABL301. The company is headquartered in Seongnam, South Korea.
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY |
|---|---|---|
| 2024‑12 | 2023‑12 | |
| Income | ||
Revenues | 33,403,030 -49.04% | 65,547,055 |
Cost of revenue | 84,154,167 | 60,025,011 |
Unusual Expense (Income) | ||
NOPBT | (50,751,137) | 5,522,044 |
NOPBT Margin | 8.42% | |
Operating Taxes | ||
Tax Rate | ||
NOPAT | (50,751,137) | 5,522,044 |
Net income | (55,529,348) 1,998.09% | (2,646,663) |
Dividends | ||
Dividend yield | ||
Proceeds from repurchase of equity | 145,857,143 | 1,716,982 |
BB yield | ||
| Debt | ||
Debt current | 43,637,486 | (31,129,924) |
Long-term debt | 689,084 | 44,091,523 |
Deferred revenue | ||
Other long-term liabilities | 1,309,307 | 1,151,847 |
Net debt | (11,990,403) | (60,946,805) |
| Cash flow | ||
Cash from operating activities | (69,402,667) | (28,361,975) |
CAPEX | (9,023,306) | (5,739,981) |
Cash from investing activities | (47,174,420) | 29,883,582 |
Cash from financing activities | 144,572,108 | 1,436,848 |
FCF | (60,122,553) | |
| Balance | ||
Cash | 141,512,482 | 71,165,345 |
Long term investments | (85,195,509) | 2,743,059 |
Excess cash | 54,646,822 | 70,631,051 |
Stockholders' equity | (371,274,175) | (289,680,536) |
Invested Capital | 583,526,551 | 408,849,491 |
ROIC | 1.35% | |
ROCE | 4.63% | |
| EV | ||
Common stock shares outstanding | 47,985 | 47,844 |
Price | ||
Market cap | ||
EV | ||
EBITDA | (48,341,199) | 8,111,822 |
EV/EBITDA | ||
Interest | 36,044 | 2,150,649 |
Interest/NOPBT | 38.95% | |